Source comparison
CJC-1295 Ipamorelin for Anti-Aging: Peptide Type Comparison
CJC-1295 DAC GHRH analog with drug-affinity complex modification. Extends GHRH receptor occupancy 6–8 days Sustained elevation in baseline GH and IGF-1 levels; promotes collagen synthesis and fat oxidation Once weekly subcutaneous injection Foundation compound
This comparison does not assign a generated winner or score.
- CJC-1295 DAC
- GHRH analog with drug-affinity complex modification. Extends GHRH receptor occupancy
- 6–8 days
- Sustained elevation in baseline GH and IGF-1 levels; promotes collagen synthesis and fat oxidation
- Once weekly subcutaneous injection
- Foundation compound. Provides consistent GH amplification without daily dosing burden
- Ipamorelin
- Selective ghrelin receptor agonist. Triggers acute pulsatile GH release from pituitary
- 2 hours
- Mimics natural GH pulses; enhances muscle protein synthesis and deep sleep architecture
- Daily subcutaneous injection (typically before bed)
- Synergistic with CJC-1295. Creates physiological pulsatility that matches youthful secretion patterns
- Sermorelin
- Unmodified GHRH analog. Stimulates natural GH release but rapidly degraded
- 8–12 minutes
- Short-duration GH pulse; limited IGF-1 response compared to DAC-modified analogs
- Multiple daily injections required for sustained effect
- Less practical than CJC-1295 due to rapid enzymatic breakdown. Clinical use has largely shifted to DAC formulations
- Tesamorelin
- FDA-approved GHRH analog for lipodystrophy. No DAC modification
- 26–38 minutes
- Visceral fat reduction; modest effect on lean mass
- Daily subcutaneous injection
- Only GHRH analog with FDA approval but narrow indication. Used off-label for anti-aging with similar profile to sermorelin
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic. Non-peptide small molecule
- 4–6 hours (oral bioavailability)
- Increases appetite and GH secretion; elevates IGF-1 sustainably
- Once-daily oral dosing
- Convenience of oral administration but causes significant hunger and potential insulin resistance with chronic use